retatrutide triple agonist gip glp-1 glucagon phase 2 obesity Agonism Based Therapies for | Current Cardiovascular Risk Reports Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

Treatment of diet-induced obese mice systemically with a potent NNMT inhibitor significantly reduced body weight and white adipose mass, decreased adipocyte size, and lowered plasma total cholesterol levels

These studies contribute to a broader understanding of growth factor signaling and molecular regulation under controlled experimental conditions

10.1038/s41569-018-0030-z Summary Keywords D-Gal, endothelial cell senescence, FOXO4-DRI, P53, ROS Citation Hu Z, Li F, Hu C, Shan Q, Tang Z, Jiang M, Yi X, Chen X, Jin L, Wang X and Wang Y (2026) FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway

Ideal levels are between 6-9 umol/L of homocysteine